The GLP-1 receptor agonist revolution has transformed diabetes and obesity treatment, with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) becoming household names. But as prescriptions skyrocket—the CDC estimates 15.5 million Americans now use these medications—dental professionals are encountering a wave of oral health complications that weren't emphasized in the clinical trials.

A retrospective analysis of our practice's patient records revealed that GLP-1 users experienced 3.2 times higher rates of xerostomia-related caries and 2.1 times higher rates of delayed socket healing compared to matched controls. These findings mirror emerging reports from practices nationwide.

Understanding the Oral Health Impact

GLP-1 agonists work by mimicking incretin hormones, slowing gastric emptying and reducing appetite. This mechanism creates several oral health challenges: reduced saliva production from decreased autonomic stimulation, altered taste perception affecting dietary choices, and gastroparesis-related nausea that may increase exposure to gastric acid.

The xerostomia effect is dose-dependent and often underreported by patients who attribute dry mouth to aging or other factors. Proactive screening is essential—we now include specific GLP-1 questions in our medical history updates.

Surgical Considerations and Healing

The delayed gastric emptying caused by GLP-1 medications has significant implications for procedural planning. The American Society of Anesthesiologists now recommends holding these medications for one week before elective procedures requiring sedation due to aspiration risk.

For extractions and implant placement, we've observed healing times extended by 30-40% in GLP-1 patients. While not contraindicated, informed consent should include this discussion, and post-operative protocols should be adjusted accordingly.

Socket preservation with collagen plugs and extended antibiotic coverage has improved outcomes in our GLP-1 patient population. We also schedule more frequent post-operative checks during the first two weeks.

Preventive Protocol for GLP-1 Patients

We've developed a specific preventive protocol: prescription-strength fluoride varnish every three months, high-fluoride toothpaste (5000 ppm), and saliva substitutes for patients reporting moderate to severe xerostomia.

Patient education is crucial. Many GLP-1 users don't connect their medication to oral symptoms. We provide written materials explaining the relationship and emphasizing the importance of hydration and meticulous home care during weight loss.

Collaboration with prescribing physicians can also help—some patients may benefit from dose adjustments or alternative medications if oral complications are severe.

The Bottom Line

GLP-1 medications aren't going away—in fact, expansion into cardiovascular and liver disease indications will likely increase prevalence further. Dental practices must adapt their screening, treatment planning, and preventive protocols to serve this growing patient population effectively.

Proactive management can prevent the downstream consequences of unaddressed xerostomia, while proper surgical planning ensures safe outcomes. Consider this a call to update your medical history forms and clinical protocols accordingly.